B-ALL [9], CLL [63], MCL [62], DLBCL [64], follicular lymphoma (FL) [65], small lymphocytic lymphoma (SLL) [63], Burkitt’s lymphoma [66], and even MM [67] are all among hematologic malignancies in which CD19 targeting can be leveraged for therapeutic purposes. This evidence concerns the gene CD19 and Burkitt lymphoma.